chen, chenyan – eisai china lnc.-乐橙pc客户端下载

entries by

eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.

eisai has grown smoothly since entering the chinese market in the early 1990s and the total …

lenvima® plus everolimus also showed statistically significant improvement in pfs and orr endpoints versus sunitinib
results of investigational phase 3 clear trial (study 307)/keynote-581 to be presented at upcoming medical meeting

if approved, aducanumab would become the first therapy to reduce the clinical decline of alzheimer’s disease and to meaningfully change the course of alzheimer’s disease

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (aβ) protofibril antibody lecanemab (development code: ban2401), at the 13th clinical trials on alzheimer’s disease (ctad) conference to be held virtually from november 4 to 7, 2020.

amgen and eisai to participate in the immune modulation domain of remap-covid, an adaptive clinical trial to test interventions for patients hospitalized with covid-19

amgen’s apremilast and eisai’s eritoran to be evaluated across multiple international trial sites within the remap network

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and cogstate, ltd. (headquarters: melbourne, australia and new haven, usa, ceo: brad o’connor, “cogstate”) announced today that the companies have entered into a collaboration whereby eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by cogstate, including the “cogstate brief batterytm” (cbb) for use in healthcare and other markets.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that biogen (nasdaq: biib) has disclosed its submission of the marketing authorization application (maa) to the european medicines agency (ema) for the review of aducanumab, an investigational treatment for alzheimer’s disease, as of october 2020 in its q3 2020 earnings press release issued on october 21. this maa is subject to validation of whether the ema accepts the application for review, which biogen plans to announce when notified.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (aed) fycompa® (product name in china: 卫克泰®, generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in china by the national medical products administration.

the university of tokyo (president: makoto gonokami, “the university of tokyo”) and eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “protein degradation drug discovery”. the research time span will last five years from october 1, 2020 to september 30, 2025.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a joint research agreement with four research organizations (kan research institute, national center for global health and medicine, nagasaki university, and yokohama city university) in japan concerning the “development of therapeutics to prevent the aggravation of the novel coronavirus infectious disease (covid-19)” (grant number: 20fk0108255), which is a research project with eisai as the representative research organization.